Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + lomustine + vincristine
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents: - 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis) - Lomustine (also known as CCNU, an alkylating nitrosourea that crosslinks DNA and RNA) - Vincristine (a vinca alkaloid that inhibits microtubule formation in mitosis) The combination has been studied primarily as adjuvant or palliative therapy for colorectal cancer, particularly in the postoperative setting for Dukes' C colorectal cancer. The regimen aims to target tumor cells through multiple mechanisms—disrupting DNA synthesis and function as well as inhibiting cell division. However, clinical trials have shown no significant improvement in survival compared to no adjuvant therapy in this context[1][3][4]. Side effects are common and can lead to discontinuation of treatment.
- Other names
- 5-fluorouracil + CCNU + vincristine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on 5-fluorouracil + lomustine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + lomustine + vincristine.